INTRODUCTION
Psoriasis affects approximately 1.2 million people in the UK [1] . The profound impact of psoriasis on mental health, well-being and quality of life is increasingly recognised [2] [3] [4] .
The burden of living with psoriasis is equivalent or greater than that of other long-term conditions such as congestive cardiac failure and chronic lung disease [5] , but tends to be under-recognised [6] . There is limited evidence regarding the management of stress and distress associated with psoriasis [7] and even less scope within our present health system for psychological intervention [8] .
This article reviews the relationship between distress and psoriasis, exploring the life impact of psoriasis and the current evidence for pharmacological and psychological interventions in this population. Papers from peer-reviewed journals have been used to inform the text and all interventional studies cited are from controlled trials.
PSYCHOLOGICAL IMPACT OF PSORIASIS

Stress and Psoriasis
Distress, in the form of excessive worrying, impairs clearance of psoriasis during phototherapy [9] . Retrospective studies have demonstrated that 37-88% of patients believe that their psoriasis is caused or exacerbated by stress [10] [11] [12] . In prospective studies, Verhoeven et al. [13] confirmed that daily stressors trigger increased itch and psoriasis severity, and that patients with high levels of worrying are most vulnerable to the impact of stressors [14] .
Psychoneuroimmunology: The Brain-Skin Axis ( Fig. 1) The stress response is an evolutionary mechanism enabling both a rapid (fight or flight) response to an acute stressor (e.g.
avoiding a predator) and a response to chronic stress by saving energy [15] . Modern day stressors trigger established pathophysiological pathways, which can act as exacerbating or causative factors in inflammatory disease [16] .
Hypothalamic-Pituitary-Adrenal Axis
Activation of neuro-hormones by stress is predominantly via the hypothalamic- 
Psychiatric Co-Morbidity
The prevalence of depression in psoriasis is estimated to be up to 30% [29] . Fortune et al. [30] identified 38% of 140 patients with psoriasis as pathological worriers, while Gupta and Gupta [31] found that 5.5% of patients with psoriasis had active suicidal ideation and that 9.5% expressed a death wish. 
Disease Severity and Psychological Impact
Psychological and psychiatric symptoms are generally in keeping with disease severity [33, 34] , but not universally [33, 35] . In a prospective study of 72 patients undergoing phototherapy, Fortune et al. [36] demonstrated significant improvement in psoriasis, without change in anxiety, depression or worrying. In another prospective study, Gupta et al. [35] found that 16 of 98 patients receiving phototherapy had persistent or worsening psoriasis disability index scores despite an improvement in psoriasis. Sampogna et al. [33] reported persistent psychiatric disorder with clearance of psoriasis in one-third of subjects.
The lack of correlation between psychological impact and physical severity in some patients may be due to the cumulative impact of living with psoriasis [2] , maintenance of distress by established maladaptive schemas and coping responses [32] , or by psoriasis affecting 'high impact' sites [37] . Lower levels of distress have been reported with longer disease duration [38, 39] , which may indicate psychological acceptance, or reflect long-term adaptation [40] and avoidance of activities that trigger distress. The latter hypothesis is supported by Kleyn et al. [41] in a study using functional magnetic resonance imaging, which demonstrated reduced signal responses to disgusted faces in patients with psoriasis compared with controls, suggesting coping mechanisms among those with psoriasis to prevent distress when seeing disgusted facial expressions.
Recognition of Distress by Clinicians
Clinicians and patients may differ in their assessment of disease severity and healthrelated quality of life (HRQoL). In a study comparing a checklist completed by both dermatologists and patients [42] , patients ranked ''embarrassment over one's appearance'' as the most severe feature of psoriasis, whereas dermatologists ranked it the lowest feature.
Patient-, rather than clinician-rated severity is the strongest predictor of HRQoL impairment [2, 33, 43] . Richards et al. [44] The discrepancy between patients and clinicians is probably multi-factorial. Patients' own underlying perceptions of illness, coping strategies [43] [44] [45] [46] , personality traits [32] , and body shame contribute to distress and are factors often unexplored by clinicians.
Richards et al. [47] found that 33% of 300 patients with psoriasis had alexithymia (impaired ability to build mental representations of emotions and express emotions). This may limit a patient's ability to communicate emotions effectively and lead to the misinterpretation of emotional arousal as physical illness. People with psoriasis may be reluctant to disclose personal information through fear of rejection and previous experience of clinicians' lack of empathy [3, 45] .
SOCIAL IMPACT OF PSORIASIS
Stigmatisation
Psoriasis may attract attention, and cause avoidance, public rejection and reactions of disgust. Ginsburg and Link [48] identified six main areas associated with stigma: anticipation of rejection; feelings of being flawed; sensitivity to others' attitudes; guilt and shame; secretiveness; and positive attitudes. The main predictors of stigma were: younger age at onset; extent of bleeding; employment status; duration of disease; and rejection experience. Hrehoró w et al. [49] repeated the study in 2012
and found that over 78% of patients had high levels of stigmatisation. Stigmatising experiences appear to be very common.
Ginsburg et al. [50] found that 99 of 100 patients described experiencing stigmatising events and Gupta et al. [51] reported that 26% of patients had experienced public rejection.
Recently, Sampogna et al. [3] found that 37% of patients experienced humiliation often or all the time, and that shame was one of the most frequently reported emotions. In a cross-sectional study of 92 male patients with psoriasis, Goulding et al. [56] found an increased prevalence of erectile dysfunction (ED) (58%) compared with controls with other skin conditions (49%). Psoriasis was not an independent risk factor for ED. The link between psoriasis, ED and atherosclerosis was suggested as a mechanism for sexual dysfunction.
Difficulties in relationships are unsurprising in a condition with high levels of distress and stigma. Despite this, the quality of relationships and sexual functioning are not routinely included in consultations or as outcomes of studies.
Employment and Financial Burden
The choice of employment or career, and therefore income, is affected by psoriasis [57] [58] [59] . In one study, 40% of patients reported experiencing major difficulties at work [52] and in another, 2% stopped work due to psoriasis [57] .
There is an inverse relationship between psoriasis severity, employment and income [59] [60] [61] [62] . In a study of 601 patients by Horn et al., 31.2% of patients with severe psoriasis had a low income (less than US$30,000) compared with 18.1% of patients with mild psoriasis [59] . Approximately 20% were unemployed. Significantly more patients with severe psoriasis (17%) reported their psoriasis as the reason for unemployment compared with patients with mild psoriasis (6%).
Though the results were consistent with other studies [60] [61] [62] , its cross-sectional design prevents determination of causal relationships.
Recently, biological intervention studies have incorporated broader 'life impairment' outcomes into their study designs. Psoriasisrelated work productivity and activity impairment (WPAI) are significantly improved by treatment with adalimumab [61] . Treatment with ustekinumab is linked with an improvement in productivity and reduced absenteeism [60] . Both studies show strong correlations between disease severity and work disability. Kimball et al. [61] reported that a reduction in Dermatology Life Quality Index (DLQI) was more highly correlated with WPAI outcomes than an improvement in Psoriasis Area Severity Index (PASI) score, and Reich et al.
[60] reported a greater improvement in WPAI outcomes in patients with higher DLQI scores and Hospital Anxiety and Depression Score at baseline, suggesting that a reduction in work disability may only be partially attributable to an improvement in disease severity.
Alcohol and Smoking Misuse
Alcohol and cigarette misuse are common among patients with psoriasis [63, 64] . Kirby et al. [65] reported excess alcohol consumption to be up to 50%. Mills et al. [66] found that twice as many patients with psoriasis smoked compared with controls. Alcohol exacerbates psoriasis severity and pruritus, and impairs treatment response [67] . Poikolainen et al. [68] demonstrated an increased standardised mortality ratio in all parameters of alcoholand smoking-related causes in people with psoriasis. Naldi et al. [69] found that the risk of psoriasis was higher (but not significantly) for current smokers and drinkers, and a trend for increased risk of psoriasis with increased usage of cigarettes and alcohol [70] .
TREATMENT OF PSYCHOLOGICAL DISTRESS IN PSORIASIS
Pharmacological Interventions
Biological Agents TNF-a antagonists are safe and effective in improving both the physical severity of psoriasis and HRQoL [71] [72] [73] . Patients with depression also have increased levels of TNF-a [74] . It is speculated that TNF is related to fatigue and sleepiness, and may account for the coexistence of depression with fatigue [75, 76] . [80] . Reduced depression and anxiety scores, and pruritus and PASI scores were seen in the escitalopram plus psychotherapeutic support group compared with psychotherapeutic support only. No details of the 'psychotherapeutic support' were given and randomisation was by patient preference.
The evidence for psychotropic medications and psoriasis is conflicting, with several casereports of fluoxetine-induced or -exacerbated psoriasis [81] [82] [83] , while the atypical antidepressant, bupropion, has been linked to exacerbations of psoriasis [84] . In addition, the mood stabiliser, lithium, commonly precipitates or aggravates psoriasis [85] .
Psychological Interventions
Despite the association of distress with psoriasis, evidence for a 'brain-skin axis' and the effect of stress on immune functioning and disease severity, there have been few high-quality studies investigating the effectiveness of psychological interventions. A recent metaanalysis of psychological interventions designed to improve skin condition outcomes identified only eight studies involving psoriasis that fulfilled the criteria of having a control group, being published in a peer-reviewed journal and written in English [7] . The majority of these studies had small sample sizes and non-randomised study designs. A diverse range of psychological interventions with differing outcomes were included, making comparisons impossible.
Psychological interventions can be divided into those addressing cognitive and behavioural processes-cognitive behaviour therapy (CBT)-and those targeting a reduction in stress (arousal reduction).
Arousal Reduction
A prospective, randomised, single-blinded study by Kabat-Zinn et al. [86] introduced a mindfulness meditation-based stress reduction audio-tape intervention as an adjunct to phototherapy and compared it to phototherapy alone. A significant improvement in the rate of psoriasis clearance and a non-significant reduction in stress levels were found. The duration of remission was not assessed. appropriate'', and recommends at least annual screening for depressive symptoms [100] .
Despite high levels of psychological distress, the provision of psychology services in the UK for patients with skin disease is, at best, limited.
In spite of clear demand, only 4% of dermatology units in the UK provide a dedicated counselling service [101] . Despite attempts to increase awareness and the provision of resources by groups such as the 
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